Bioatla to participate in the 2022 btig biotechnology conference

San diego, aug. 03, 2022 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced that the company's management will participate in a fireside chat at the 2022 btig biotechnology conference, to be held in new york, ny monday, august 8, 2022.
BCAB Ratings Summary
BCAB Quant Ranking